Ovarian cancer statistics, 2018
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel, Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel
Abstract
In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population-based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non-Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5-year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018;68:284-296. © 2018 American Cancer Society.
Keywords: epidemiology; epithelial ovarian cancers; health disparities; ovarian neoplasms.
© 2018 American Cancer Society.
Figures
![Figure 1. Ovarian Cancer Incidence and Mortality…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6621554/bin/nihms-1039849-f0001.jpg)
![Figure 2. Age-adjusted Ovarian Cancer Delay-adjusted Incidence…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6621554/bin/nihms-1039849-f0002.jpg)
Figure 3. Distribution (%) of Ovarian Cancer…
Figure 3. Distribution (%) of Ovarian Cancer Cases* by Major Subtype and Race/ethnicity, 2010–2014
*Data…
Figure 4. Epithelial Ovarian Cancer Incidence Rates*…
Figure 4. Epithelial Ovarian Cancer Incidence Rates* by Age, Race/ethnicity, and Histology, US, 2010–2014
*Per…
Figure 5. AJCC* Stage Distribution (%) for…
Figure 5. AJCC* Stage Distribution (%) for Ovarian Cancer by Histology, US, 2007–2013
*6 th…
Figure 6. Non-epithelial Ovarian Cancer Incidence Rates*…
Figure 6. Non-epithelial Ovarian Cancer Incidence Rates* by Age, Race/ethnicity, and Histology, US, 2010–2014
*Per…
- Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities.DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A. DeSantis CE, et al. CA Cancer J Clin. 2016 Jul;66(4):290-308. doi: 10.3322/caac.21340. Epub 2016 Feb 22. CA Cancer J Clin. 2016. PMID: 26910411
- Colorectal cancer statistics, 2014.Siegel R, Desantis C, Jemal A. Siegel R, et al. CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17. doi: 10.3322/caac.21220. Epub 2014 Mar 17. CA Cancer J Clin. 2014. PMID: 24639052
- Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA. Ryerson AB, et al. Cancer. 2016 May 1;122(9):1312-37. doi: 10.1002/cncr.29936. Epub 2016 Mar 9. Cancer. 2016. PMID: 26959385 Free PMC article.
- Cancer statistics, 2018.Siegel RL, Miller KD, Jemal A. Siegel RL, et al. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4. CA Cancer J Clin. 2018. PMID: 29313949
- Breast cancer statistics, 2013.DeSantis C, Ma J, Bryan L, Jemal A. DeSantis C, et al. CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62. doi: 10.3322/caac.21203. Epub 2013 Oct 1. CA Cancer J Clin. 2014. PMID: 24114568 Review.
- Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.Millar DG, Yang SYC, Sayad A, Zhao Q, Nguyen LT, Warner K, Sangster AG, Nakatsugawa M, Murata K, Wang BX, Shaw P, Clarke B, Bernardini MQ, Pugh T, Thibault P, Hirano N, Perreault C, Ohashi PS. Millar DG, et al. Cancer Immunol Immunother. 2023 Mar 21. doi: 10.1007/s00262-023-03413-7. Online ahead of print. Cancer Immunol Immunother. 2023. PMID: 36943460
- MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.Chen K, Yuan X, Wang S, Zheng F, Fu Z, Shen Z, Cheng X, Wang Y, Tang S, Ni H, Wang F, Lu G, Wu Y, Xia D, Lu W. Chen K, et al. Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650-5. Online ahead of print. Oncogene. 2023. PMID: 36922678
- MicroRNA-592 Inhibits the Growth of Ovarian Cancer Cells by Targeting ERBB3.Jin Q, Zhang N, Zhan Y, Xu X, Han C, Zhao H, Hu X, Tang H, Wu Y. Jin Q, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231157156. doi: 10.1177/15330338231157156. Technol Cancer Res Treat. 2023. PMID: 36916303 Free PMC article.
- Safety Analysis of Bevacizumab in Ovarian Cancer Patients.Wang Y, Lin H, Ou Y, Fu H, Tsai C, Chien CC, Wu C. Wang Y, et al. J Clin Med. 2023 Mar 6;12(5):2065. doi: 10.3390/jcm12052065. J Clin Med. 2023. PMID: 36902852 Free PMC article.
- Characterization of Primary Mucinous Ovarian Cancer by Diffusion-Weighted and Dynamic Contrast Enhancement MRI in Comparison with Serous Ovarian Cancer.Grabowska-Derlatka L, Derlatka P, Hałaburda-Rola M. Grabowska-Derlatka L, et al. Cancers (Basel). 2023 Feb 24;15(5):1453. doi: 10.3390/cancers15051453. Cancers (Basel). 2023. PMID: 36900244 Free PMC article.
- Adult
- Aged
- Aged, 80 and over
- American Cancer Society
- Carcinoma / diagnosis
- Carcinoma / epidemiology*
- Early Detection of Cancer
- Female
- Health Status Disparities
- Humans
- Incidence
- Middle Aged
- Ovarian Neoplasms / diagnosis
- Ovarian Neoplasms / epidemiology*
- Prognosis
- United States / epidemiology
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Figure 3. Distribution (%) of Ovarian Cancer…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6621554/bin/nihms-1039849-f0003.jpg)
![Figure 4. Epithelial Ovarian Cancer Incidence Rates*…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6621554/bin/nihms-1039849-f0004.jpg)
Figure 5. AJCC* Stage Distribution (%) for…
Figure 5. AJCC* Stage Distribution (%) for Ovarian Cancer by Histology, US, 2007–2013
*6 th…
Figure 6. Non-epithelial Ovarian Cancer Incidence Rates*…
Figure 6. Non-epithelial Ovarian Cancer Incidence Rates* by Age, Race/ethnicity, and Histology, US, 2010–2014
*Per…
- Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities.DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A. DeSantis CE, et al. CA Cancer J Clin. 2016 Jul;66(4):290-308. doi: 10.3322/caac.21340. Epub 2016 Feb 22. CA Cancer J Clin. 2016. PMID: 26910411
- Colorectal cancer statistics, 2014.Siegel R, Desantis C, Jemal A. Siegel R, et al. CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17. doi: 10.3322/caac.21220. Epub 2014 Mar 17. CA Cancer J Clin. 2014. PMID: 24639052
- Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA. Ryerson AB, et al. Cancer. 2016 May 1;122(9):1312-37. doi: 10.1002/cncr.29936. Epub 2016 Mar 9. Cancer. 2016. PMID: 26959385 Free PMC article.
- Cancer statistics, 2018.Siegel RL, Miller KD, Jemal A. Siegel RL, et al. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4. CA Cancer J Clin. 2018. PMID: 29313949
- Breast cancer statistics, 2013.DeSantis C, Ma J, Bryan L, Jemal A. DeSantis C, et al. CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62. doi: 10.3322/caac.21203. Epub 2013 Oct 1. CA Cancer J Clin. 2014. PMID: 24114568 Review.
- Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.Millar DG, Yang SYC, Sayad A, Zhao Q, Nguyen LT, Warner K, Sangster AG, Nakatsugawa M, Murata K, Wang BX, Shaw P, Clarke B, Bernardini MQ, Pugh T, Thibault P, Hirano N, Perreault C, Ohashi PS. Millar DG, et al. Cancer Immunol Immunother. 2023 Mar 21. doi: 10.1007/s00262-023-03413-7. Online ahead of print. Cancer Immunol Immunother. 2023. PMID: 36943460
- MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.Chen K, Yuan X, Wang S, Zheng F, Fu Z, Shen Z, Cheng X, Wang Y, Tang S, Ni H, Wang F, Lu G, Wu Y, Xia D, Lu W. Chen K, et al. Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650-5. Online ahead of print. Oncogene. 2023. PMID: 36922678
- MicroRNA-592 Inhibits the Growth of Ovarian Cancer Cells by Targeting ERBB3.Jin Q, Zhang N, Zhan Y, Xu X, Han C, Zhao H, Hu X, Tang H, Wu Y. Jin Q, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231157156. doi: 10.1177/15330338231157156. Technol Cancer Res Treat. 2023. PMID: 36916303 Free PMC article.
- Safety Analysis of Bevacizumab in Ovarian Cancer Patients.Wang Y, Lin H, Ou Y, Fu H, Tsai C, Chien CC, Wu C. Wang Y, et al. J Clin Med. 2023 Mar 6;12(5):2065. doi: 10.3390/jcm12052065. J Clin Med. 2023. PMID: 36902852 Free PMC article.
- Characterization of Primary Mucinous Ovarian Cancer by Diffusion-Weighted and Dynamic Contrast Enhancement MRI in Comparison with Serous Ovarian Cancer.Grabowska-Derlatka L, Derlatka P, Hałaburda-Rola M. Grabowska-Derlatka L, et al. Cancers (Basel). 2023 Feb 24;15(5):1453. doi: 10.3390/cancers15051453. Cancers (Basel). 2023. PMID: 36900244 Free PMC article.
- Adult
- Aged
- Aged, 80 and over
- American Cancer Society
- Carcinoma / diagnosis
- Carcinoma / epidemiology*
- Early Detection of Cancer
- Female
- Health Status Disparities
- Humans
- Incidence
- Middle Aged
- Ovarian Neoplasms / diagnosis
- Ovarian Neoplasms / epidemiology*
- Prognosis
- United States / epidemiology
- Full Text Sources
- Other Literature Sources
- Medical
![Figure 5. AJCC* Stage Distribution (%) for…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6621554/bin/nihms-1039849-f0005.jpg)
![Figure 6. Non-epithelial Ovarian Cancer Incidence Rates*…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6621554/bin/nihms-1039849-f0006.jpg)
Source: PubMed